ETFIQ
RankingsCompareHoldingsFlowsResearch
Ask ETFIQETF ModelsMy portfolioWeekly note
A
vs
B
Share on XDownload as PDFOpen liveCompare their flowsAsk about these two funds

IDNA vs XBI: which is really different?

IDNA and XBI hold 20% of their weight in the same names, and IDNA returned +73.5% over the year. iShares Genomics Immunology and Healthcare ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.

XBI costs 0.12 points a year less; their one-year returns differ by 28.5 points; XBI is far larger, $9.9bn against $320m.

IDNAXBI
Expense ratio0.47%0.35%
Net assets, IDNA as of Oct 9, 2026 and XBI as of Oct 8, 2026$320m$9.9bn
Total return, 1 year+73.5%+45.0%
What it tracksGenomics and gene editingBiotech
Holdings in common20%
S&P 500, total return, 1 year+17.3%
Against the S&P 500, 1 yearahead by 56.2 ptsahead by 27.7 pts
Below its all-time high20.2%, high on Sep 2, 202111.1%, high on Feb 8, 2021

Holdings in common uses holdings dated Oct 8, 2026.

25.4%
IDNA in the S&P 500
12.7%
XBI in the S&P 500
+73.5%
IDNA total return, 1 year
+45.0%
XBI total return, 1 year
IDNA · 1 year to Oct 9, 202675% of its weight is outside the S&P 500
75% of its weight is outside the S&P 50025% of IDNA's weight is in S&P 500 companies and 75% is outside the index. Holdings as of Oct 8, 2026.25%75%in the S&P 500of its weight outside the S&P 500active share 99% · top ten 48% of the fund · 52 holdings as published by its issuer for Oct 8, 2026 · Nasdaq-100: 7% in75% of its weight is outside the S&P 50025% of IDNA's weight is in S&P 500 companies and 75% is outside the index. Holdings as of Oct 8, 2026.25%75%inoutside the S&P 500active share 99% · Nasdaq-100: 7% in

25% of IDNA's weight is in S&P 500 companies and 75% is outside the index. Holdings as of Oct 8, 2026.

XBI · 1 year to Oct 9, 202687% of its weight is outside the S&P 500
87% of its weight is outside the S&P 50013% of XBI's weight is in S&P 500 companies and 87% is outside the index. Holdings as of Oct 8, 2026.13%87%inof its weight outside the S&P 500active share 98% · top ten 17% of the fund · 165 holdings as published by its issuer for Oct 8, 2026 · Nasdaq-100: 9% in87% of its weight is outside the S&P 50013% of XBI's weight is in S&P 500 companies and 87% is outside the index. Holdings as of Oct 8, 2026.13%87%inof its weight outside the S&P 500active share 98% · Nasdaq-100: 9% in

13% of XBI's weight is in S&P 500 companies and 87% is outside the index. Holdings as of Oct 8, 2026.

ETFIQ Off-Index Score · IDNA scores higherHow much of it is not the index it is sold as an alternative to?
0.1, the lowest in this set92.3, the highest

A percentile among the 391 thematic ETFs with a holdings filing. All thematic ETFs ranked by it → How it is computed →

What they hold in common

By the books each fund has filed, IDNA and XBI hold 20% of their money in the same securities at the same weight. Above 50%, holding both is close to holding one of them twice. Holdings dated Oct 8, 2026.

half

20% in common

Positions both hold, largest shared weight first
Holding IDNA XBI
MODERNA 12.11% 2.20%
TWIST BIOSCIENCE 6.40% 1.84%
IOVANCE BIOTHERAPEUTICS INC 4.72% 1.54%
EXELIXIS INC 3.26% 1.53%
VERTEX PHARMACEUTICALS 3.28% 1.47%
REGENERON PHARMACEUTICALS 3.39% 1.39%
REVOLUTION MEDICINES 3.67% 1.37%
INCYTE CORP 3.21% 1.36%
CRISPR THERAPEUTICS AG 1.32% 1.41%
IMMUNITYBIO 3.41% 1.19%
IDEAYA BIOSCIENCES 2.74% 0.59%
NOVAVAX 1.58% 0.52%
Only in IDNA
GENMAB 4.18%
TAKEDA PHARMACEUTICAL 3.48%
MERCK & CO INC 3.44%
BAYER AG 3.33%
CARIS LIFE SCIENCES 3.08%
BIONTECH SE ADR 3.05%
ROCHE PS PAR AG 3.00%
ABCELLERA BIOLOGICS 2.58%
Only in XBI
NATERA INC 1.79%
ABBVIE INC 1.65%
UNITED THERAPEUTICS CORP 1.59%
AMGEN INC 1.58%
BIOGEN INC 1.57%
HALOZYME THERAPEUTICS INC 1.55%
GILEAD SCIENCES INC 1.53%
TG THERAPEUTICS INC 1.48%

20% of the two portfolios are the same securities at the same weight.

Performance, window by window

Total returnvs the S&P 500vs the Nasdaq-100
WindowIDNAXBIIDNAXBIIDNAXBI
3 months+25.7%−3.3%+22.3 pts−6.7 pts+22.0 pts−7.0 pts
6 months+44.4%+18.9%+29.3 pts+3.8 pts+21.2 pts−4.3 pts
1 year+73.5%+45.0%+56.2 pts+27.7 pts+49.9 pts+21.4 pts
3 years+117.5%+114.6%+31.7 pts+28.8 pts+10.2 pts+7.3 pts
Since launch
IDNA Jun 2019 · XBI Feb 2006
+79.7%+890.7%−120.4 pts+92.2 pts−249.5 pts−1,164.7 pts

Source: ETFIQ. Open the live comparison on ETFIQ →

On the same fields

IDNA
iShares Genomics Immunology and Healthcare ETF · Holds 52 stocks in genomics and gene editing, 25% of its weight in S&P 500 companies
XBI
State Street(R) SPDR(R) S&P(R) Biotech ETF · Holds 165 stocks in biotech, 13% of its weight in S&P 500 companies
Issuer iShares State Street
Theme Genomics and gene editing Biotech
In the S&P 500 25.4% 12.7%
Active share vs the S&P 500 99.1% 98.4%
In the Nasdaq-100 6.7% 8.5%
Holdings 52 165
Top ten, share of the fund 48.1% 16.9%
Expense ratio 0.47% 0.35%
Fee for the differing part 0.47% 0.36%
Total return, 1 year +73.5% +45.0%
vs the S&P 500 +56.2 pts +27.7 pts
vs the Nasdaq-100 +49.9 pts +21.4 pts
Below its high −20.2% −11.1%
Net assets, IDNA as of Oct 9, 2026 and XBI as of Oct 8, 2026 $320m $9.9bn

As of Oct 9, 2026. Source: ETFIQ.

IDNA in plain words

By weight, 25% of IDNA's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 48% of the fund across 52 positions, as published by its issuer for Oct 8, 2026. Over the year to Oct 9, 2026 the fund returned +73.5% with distributions reinvested against +17.3% for the S&P 500, so a holder was ahead by 56.2 pts. It sits 20.2% below its all-time high of Sep 2, 2021.

XBI in plain words

By weight, 13% of XBI's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 17% of the fund across 165 positions, as published by its issuer for Oct 8, 2026. Over the year to Oct 9, 2026 the fund returned +45.0% with distributions reinvested against +17.3% for the S&P 500, so a holder was ahead by 27.7 pts. It sits 11.1% below its all-time high of Feb 8, 2021.

Questions people ask

Do IDNA and XBI hold the same stocks?
By their latest filings, 20% of their books are the same securities at the same weight, which is a meaningful overlap. Overlap is the sum of the smaller weight of every security they share.
Which is more different from the S&P 500, IDNA or XBI?
IDNA has 25% of its weight in S&P 500 names and XBI has 13%, so IDNA differs more from the index.
Which is cheaper, IDNA or XBI?
IDNA charges 0.47% a year and XBI charges 0.35%, so XBI is cheaper. Fees come from each fund's prospectus.
Other comparisons
IDNA vs IBBIDNA vs PBPHIDNA vs BBCIDNA vs FBTXBI vs ARKGXBI vs GNOMXBI vs GNMXXBI vs IDEF
IDNA on its own →XBI on its own →How every figure is computed →Standards and sources →
Where these figures came from
IDNA filings on SEC EDGAR ↗IDNA prospectus with the expense ratio (SEC) ↗iShares page for IDNA ↗XBI filings on SEC EDGAR ↗XBI prospectus with the expense ratio (SEC) ↗State Street website ↗

ETFIQ links to the documents behind every figure; a link is not an endorsement. A comparison is not a recommendation.

How this is computed

It is a position in a set, not a rating, and neither end of it is a recommendation.

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed.

Every figure is an ETFIQ calculation with distributions reinvested.

Cite this page

ETFIQ, IDNA against XBI, data as of Oct 9, 2026. https://etfiq.com/compare/themes/idna-vs-xbi

Open data

Free to use with attribution for figures ETFIQ computes; issuer data stays under its owner's terms.